No Clinical or Molecular Evidence of Plasmodium falciparum Resistance to Artesunate-Mefloquine in Northwestern Brazil

We evaluated the clinical efficacy of artesunate-mefloquine (ASMQ) fixed-dose combination to treat uncomplicated malaria in Juruá Valley, the main Plasmodium falciparum transmission hotspot in Brazil. Between November 2010 and February 2013, we enrolled 162 patients aged 4-73 years, with fever or a...

Full description

Saved in:

Bibliographic Details
Published in:	The American journal of tropical medicine and hygiene Vol. 95; no. 1; pp. 148 - 154
Main Authors:	Ladeia-Andrade, Simone, de Melo, Gladson Naber P, de Souza-Lima, Rita de Cássia, Salla, Laís C, Bastos, Melissa S, Rodrigues, Priscila T, Luz, Francisco das Chagas O, Ferreira, Marcelo U
Format:	Journal Article
Language:	English
Published:	United States The American Society of Tropical Medicine and Hygiene 06-07-2016
Subjects:	Adolescent Adult Aged Antimalarials - therapeutic use Artemisinins - therapeutic use Brazil Child Child, Preschool DNA, Protozoan - isolation & purification Dose-Response Relationship, Drug Drug Combinations Fever - drug therapy Follow-Up Studies Humans Malaria, Falciparum - drug therapy Mefloquine - therapeutic use Middle Aged Multidrug Resistance-Associated Proteins - genetics Multidrug Resistance-Associated Proteins - metabolism Parasitemia - drug therapy Plasmodium falciparum Plasmodium falciparum - drug effects Plasmodium falciparum - genetics Treatment Outcome Young Adult ASW, Brazil
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	We evaluated the clinical efficacy of artesunate-mefloquine (ASMQ) fixed-dose combination to treat uncomplicated malaria in Juruá Valley, the main Plasmodium falciparum transmission hotspot in Brazil. Between November 2010 and February 2013, we enrolled 162 patients aged 4-73 years, with fever or a history of fever, and a single-species P. falciparum infection confirmed by microscopy and polymerase chain reaction (PCR). All 154 patients who completed the 42-day follow-up presented an adequate clinical and parasitologic response. ASMQ was well tolerated and no adverse event caused treatment interruption. Gametocytes were detected in 46.3% patients; 35.2% had gametocytes at enrollment, whereas others developed patent gametocytemia 1-14 days after starting ASMQ. By day 3 of treatment, all subjects had cleared asexual parasitemia, but parasite DNA remained PCR detectable in 37.6% of them. Day-3 PCR positivity was associated with prolonged gametocyte carriage. We found no molecular evidence of resistance to either MQ (pfmdr1 gene amplification) or AS (mutations in selected kelch13 gene domains known to be associated with AS resistance) in the local P. falciparum population. These results strongly support the use of ASMQ as a first-line regimen to treat uncomplicated P. falciparum malaria in northwestern Brazil, but underscore the need for gametocytocidal drugs to reduce the transmission potential of ASMQ-treated patients (ClinicalTrials.gov number NCT01144702).
Bibliography:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Article-1 ObjectType-Feature-2
ISSN:	0002-9637 1476-1645
DOI:	10.4269/ajtmh.16-0017